Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1447028 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $4.41Day +2.80%Mkt cap $871M1Y +33.6%Off 52W high −18.0%Vol (1Y) 47.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,761 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.9% of sh out |
| Days to cover7.4d |
| 13F net flow (QoQ)+7.77% |
| Top-10 13F concentration74.2% |
| Next report (est.)2026-08-17 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$191.4M |
| Earnings (TTM)$160.7M |
| ROE−38.5% |
| Net margin−237.9% |
| Debt / equity0.00× |
| Sales growth 3Y−28.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−8.3% |
| 1Y+33.6% |
| 3Y+103.2% |
| 5Y+63.9% |
| 10Y+5.8% |
| Since incept. (ann.)−7.6% |
Total return through 2026-07-30 · series begins 2015-08-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)47.1% |
| Ann. volatility (3Y)44.3% |
| Sharpe (1Y)0.86 |
| Sharpe (3Y)0.76 |
| Max drawdown (1Y)−25.9% |
| Max drawdown (3Y)−36.8% |
| Beta (3Y vs SPY)0.45 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MORGAN STANLEY | 25.9M | $117M | 13.25% | −3.0% |
| Two Seas Capital LP | 18.6M | $84M | 9.49% | +47.4% |
| Whitefort Capital Management, LP | 14.9M | $67M | 7.64% | +11.9% |
| BlackRock, Inc. | 13.0M | $58M | 6.63% | −0.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.7M | $30M | 3.42% | new |
| Rubric Capital Management LP | 6.6M | $30M | 3.39% | +320.6% |
| STATE STREET CORP | 6.3M | $29M | 3.24% | +7.4% |
| BARCLAYS PLC | 4.3M | $19M | 2.21% | +1110.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | $0.87 | — | $179.1M | +10054.5% |
| 2025-12-31 | 2026-03-23 | — | — | $1.1M | −33.2% |
| 2025-09-30 | 2025-11-13 | −$0.04 | — | $529,000 | −60.5% |
| 2025-06-30 | 2025-08-06 | $0.01 | — | $10.7M | +522.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-17 is ESTIMATED from filing cadence (median gap 96d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
